Vickers, M M <br/><br/>
Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  Jul 2012 
 - 1434-42 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2011.10.035  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Age Factors<br/>Aged<br/>Antimetabolites, Antineoplastic--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Comorbidity<br/>Deoxycytidine--administration & dosage<br/>Erlotinib Hydrochloride<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Multivariate Analysis<br/>Neoplasm Metastasis<br/>Outcome Assessment, Health Care<br/>Pancreatic Neoplasms--complications<br/>Placebos<br/>Proportional Hazards Models<br/>Protein Kinase Inhibitors--administration & dosage<br/>Quinazolines--administration & dosage<br/>Risk<br/>Gemcitabine